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Introduction
Fibromyalgia syndrome (FMS) is a chronic pain condition char-
acterized by widespread pain, augmented pain sensitivity to 
mechanical pressure and cold temperatures (1–4), as well as 
fatigue and emotional distress (5–7). The prevalence of FMS is at 
least 2% (8), and approximately 80% of FMS patients are women. 
The prevalence rises to 10%–30% among patients diagnosed 
with autoimmune rheumatological conditions (9, 10), and FMS is 
thus one of the most common chronic pain conditions. The etiol-
ogy and pathophysiology of FMS are not completely understood 
(11) and the current treatment strategies for FMS rely mainly 
on lifestyle changes, physical exercise, and drug therapy with 
antidepressants and anticonvulsants. Unfortunately, the mod-
est efficacy of the available therapies in most patients leaves an 
enormous unmet clinical need (12, 13). The animal models that 
have been used for experimental studies of FMS have uncertain 
translational relevance and rely on local repeated intramuscu-
lar injections of acid (14) or systemic depletion of monoamines 
by reserpine treatment (15). The development of novel, mecha-
nism-based therapies has been hampered by the limited under-
standing of the basis of FMS.
The increased polymodal pain sensitivity experienced by FMS 
patients (1, 16) is associated with altered pain processing in the 
central nervous system (11), dysfunctional descending pain mod-
ulation (17, 18), and structural and functional changes in the brain 
(19–21). FMS is also associated with abnormalities in peripheral 
sensory afferents, such as spontaneous activity and sensitization of 
C-fibers, and loss of epidermal innervation (22, 23). Altered levels 
of inflammatory and immunoregulatory cytokines have also been 
reported in FMS patients. Although these alterations do not follow 
a consistent pattern (24, 25), they may suggest that immune pro-
cesses are dysregulated in patients. These observations, together 
with the markedly increased prevalence of FMS among patients 
with autoimmune rheumatological conditions (9, 10), and demon-
strations that less common (26, 27) and very rare chronic pains (28) 
are caused by autoantibodies, led us to hypothesize that FMS may 
have an autoimmune basis. Here we have investigated the possibil-
ity that autoreactive IgG is responsible for several key symptoms 
of FMS, by examining whether these can be transferred to mice by 
administration of IgG purified from FMS patients, and by assessing 
the tissue localization of IgG after passive transfer.
Fibromyalgia syndrome (FMS) is characterized by widespread pain and tenderness, and patients typically experience fatigue 
and emotional distress. The etiology and pathophysiology of fibromyalgia are not fully explained and there are no effective 
drug treatments. Here we show that IgG from FMS patients produced sensory hypersensitivity by sensitizing nociceptive 
neurons. Mice treated with IgG from FMS patients displayed increased sensitivity to noxious mechanical and cold stimulation, 
and nociceptive fibers in skin-nerve preparations from mice treated with FMS IgG displayed an increased responsiveness to 
cold and mechanical stimulation. These mice also displayed reduced locomotor activity, reduced paw grip strength, and a 
loss of intraepidermal innervation. In contrast, transfer of IgG-depleted serum from FMS patients or IgG from healthy control 
subjects had no effect. Patient IgG did not activate naive sensory neurons directly. IgG from FMS patients labeled satellite glial 
cells and neurons in vivo and in vitro, as well as myelinated fiber tracts and a small number of macrophages and endothelial 
cells in mouse dorsal root ganglia (DRG), but no cells in the spinal cord. Furthermore, FMS IgG bound to human DRG. Our 
results demonstrate that IgG from FMS patients produces painful sensory hypersensitivities by sensitizing peripheral 
nociceptive afferents and suggest that therapies reducing patient IgG titers may be effective for fibromyalgia.
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Results
Passive transfer of sensory hypersensitivities. 
IgG purified from the serum of individual 
FMS patients and healthy control (HC) sub-
jects recruited from the Walton Centre (Liv-
erpool, United Kingdom [UK]) was admin-
istered to female mice by intraperitoneal 
injection for 4 consecutive days (8 mg per 
day). This dose regimen was based on the 
original studies identifying myasthenia gra-
vis as an autoantibody-mediated disorder 
(29, 30), and more recent studies of complex 
regional pain syndrome (26, 31). Because 
FMS is characterized by hypersensitivity 
to mechanical pressure, we examined paw 
withdrawal thresholds in mice using the 
Randall-Selitto paw-pressure test following 
IgG transfer. IgG from each of the 8 indi-
vidual patients, but not from any of the 6 
HC subjects, rapidly produced mechanical 
hypersensitivity (Figure 1, A–F). In addition 
to pressure sensitivity, patients frequently 
report that pain is exacerbated by cold tem-
peratures, and quantitative sensory testing 
has demonstrated an increased cold pain 
sensitivity in FMS (1, 2, 4, 16). In good agree-
ment with patient observations, administra-
tion of IgG from 7 of the 8 FMS patients gave 
rise to a significantly increased sensitivity to 
noxious cold in mice (Figure 1, G–L). Both 
mechanical and cold hypersensitivities were 
typically established within 24–48 hours 
after the first injection and were maintained 
for more than 1 week. The observed hyper-
sensitivities produced by IgG preparations 
from different FMS patients showed sim-
ilar amplitudes and time courses (Figure 
1, A–L, and Supplemental Figure 1, A and 
B; supplemental material available online 
with this article; https://doi.org/10.1172/
Figure 1. Passive transfer of hypersensitivities 
from fibromyalgia patients to mice. Adminis-
tration of IgG (8 mg on 4 consecutive days) from 
each of 8 different FMS patients (P1–P8) signifi-
cantly reduced the withdrawal threshold in the 
paw-pressure test (A–F) compared with IgG from 
healthy control subjects (HC1–HC6). The paw with-
drawal latency in the cold-plate test was reduced 
by IgG from 7 of 8 patients (G–L). Data points are 
mean ± SEM of n = 6 mice in A, C, E, G, I, and K;  
n = 5 in D, F, J, and L; and n = 4 in B and H. *P < 
0.05, **P < 0.01, ***P < 0.001, FMS IgG compared 
with HC IgG; 2-way repeated measure ANOVA fol-
lowed by Sidak’s correction. †P < 0.05, ††P < 0.01, 
†††P < 0.001, compared with the naive preinjection 
value at time zero; 2-way repeated measure  
ANOVA followed by Dunnett’s test.
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2, 4, and 8 mg of FMS IgG, and found that only the highest dose 
increased the mechanical sensitivity in the paw-pressure test (Fig-
ure 2F). These data suggest that a single injection of 8 mg IgG may 
be sufficient to transfer mechanical hypersensitivity to mice, and 
that the effect is saturable (Figure 2E).
Since FMS is regularly associated with reduced muscular 
strength, and FMS severity is negatively correlated with handgrip 
strength (34, 35), we sought to evaluate this experimentally by 
monitoring the front paw grip strength in mice. In this test, FMS IgG 
significantly reduced grip strength compared with mice treated 
with HC IgG (Figure 2G).
To determine whether antibodies are responsible for painful 
hypersensitivities in a larger and regionally distinct cohort of FMS 
patients (recruited at the Karolinska Institute; Supplemental Table 
1), we examined the effects of IgG preparations pooled from mul-
tiple FMS patients and HC subjects. As expected, FMS patients 
displayed markedly higher pain ratings on a visual analog scale 
(VAS) (Figure 3A and Supplemental Table 2) and a significantly 
increased pressure-pain sensitivity compared with HC subjects 
(Figure 3B and Supplemental Table 2). Serum IgG isotype levels 
of FMS and HC subjects were within published normal concentra-
tion ranges (36) despite IgG1 being lower in FMS serum than in 
HC serum (for Swedish subjects; Supplemental Table 3). Admin-
istration of IgG pooled from 2 separate groups of FMS patients to 
mice (8–14 individuals per group, 2 experiments; Supplemental 
Table 2) significantly increased sensitivity in the paw-pressure test 
compared with administration of pooled IgG from groups of HC 
subjects (Figure 3C). In these experiments, we used a dose regi-
men of 8 mg IgG on 4 consecutive days. Similar to our observa-
JCI144201DS11), which is reflected in the averaged mechanical 
and cold sensitivities produced by IgG from these 8 individual 
FMS patients and 6 HC subjects measured over 10 days (Supple-
mental Figure 1, C and D). FMS IgG also generated hypersensi-
tivity to stimulation with calibrated von Frey filaments, a widely 
used test of mechanical nociception in mice (Figure 2A). Fibro-
myalgia pain is characteristically widespread, and studies of the 
bodily localization of pain have identified the thigh as one of the 
most commonly affected sites (32, 33). We therefore examined the 
pressure sensitivity of the thigh using the Randall-Selitto device 
(Figure 2B), to determine whether FMS IgG affects the pressure 
sensitivity of sites other than the hind paw in mice. In this test, 
FMS IgG produced significant mechanical hypersensitivity in the 
thigh compared with treatment with IgG from HCs (Figure 2B).
FMS is more common among women than men, and we 
therefore asked whether an increased sensitivity to the effects 
of IgG contributes to the increased incidence in females. We 
examined this possibility by comparing the effects of IgG from a 
female patient in female and male mice. We observed significant 
and indistinguishable mechanical and cold hypersensitivities 
in female and male mice (Figure 2, C and D), suggesting that 
it is unlikely that the described behavioral findings are due to 
increased female sensitivity to FMS IgG.
Hitherto, we had administered 4 injections of 8 mg IgG in all 
experiments. To identify a dose-response relationship for IgG from 
one patient, we varied the number of daily injections between 1 
and 4 (Figure 2E). In this experiment, 1, 2, and 4 injections of 8 mg 
produced essentially identical patterns of mechanical hypersensi-
tivity. We additionally examined the effects of single injections of 
Figure 2. FMS IgG produces polymodal abnormalities. FMS IgG increased the sensitivity to punctate stimulation with von Frey filaments (A). The 
threshold for leg withdrawal in response to pressure applied to the thigh (using a Randall-Selitto device) was reduced by FMS IgG compared with HC IgG 
(B). Female and male mice are affected equally by FMS IgG in the paw-pressure test (C) and the cold-plate test (D). Mechanical hypersensitivity produced 
by either 1, 2, or 4 injections of 8 mg FMS IgG (E), and by single injections of 2, 4, or 8 mg (F). The front paw grip strength is reduced by FMS IgG compared 
with HC IgG (G). Data points are mean ± SEM or individual measurements. *P < 0.05, **P < 0.01, ***P < 0.001, FMS IgG compared with HC IgG; 2-way 
repeated measure ANOVA followed by Sidak’s correction (A, C, D, and G). Data in B were analyzed by unpaired, 2-tailed t test. Data in E and F were com-
pared to the naive preinjection value at time zero by 2-way repeated measure ANOVA followed by Dunnett’s test.
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tion (Figure 3, E and F; see Supplemental Figure 1 for time course 
with IgG from an individual patient), which is consistent with the 
time course for the elimination of human IgG from mice (37).
We next compared the effects of FMS patient IgG with the 
IgG-depleted patient serum from the same individual to assess 
whether immunoglobulins and serum components other than 
IgG may contribute to pain and hypersensitivity (Figure 4). As 
expected, IgG from an FMS patient (8 mg on 4 consecutive days) 
produced marked cold and mechanical hypersensitivities, but 
IgG-depleted serum from the same patient and pooled prepara-
tions from groups of FMS patients or HC subjects were without 
any discernable behavioral effect (Figure 4, A and B).
IgG from patients reduces locomotor activity in mice. Fatigue, a 
feeling of excessive mental or physical weariness and weakness, 
is one of the key symptoms of FMS (38), but also of a wide range 
of other chronic diseases (39). FMS patients often display reduced 
levels of physical activity (40), with a loss of physical fitness as a 
consequence (41). Encouraged by the demonstration of reduced 
grip strength following administration of FMS IgG, we next exam-
ined locomotor activity of mice injected with FMS IgG or HC IgG 
over a 24-hour period. In this experiment we used pooled IgG 
from new groups of FMS patients and HC subjects (Pool 3, Sup-
plemental Table 2). Similar to the earlier 2 cohorts (see Figure 3, A 
and B), patients displayed higher VAS pain ratings and increased 
pressure-pain sensitivity compared with HC subjects (Figure 5, A 
and B, and Supplemental Table 2). Since the dose-response stud-
ies showed that 2 injections of FMS IgG were sufficient to induce 
marked mechanical hypersensitivity (see Figure 2), 8 mg of 
pooled IgG was injected intraperitoneally on 2 consecutive days. 
As expected, mice were markedly less active during the day than 
during the dark phase (18:00–6:00 hours), irrespective of whether 
they received HC or FMS IgG (Figure 5C). During the night 
(18:00–6:00 hours, when mice are most active), the total number 
of recorded movements in FMS IgG–treated mice was reduced. 
When examined in more detail, it was apparent that this reduction 
was predominantly in the most active phase (22:00–02:00 hours; 
Figure 5, D–F). These results demonstrate that FMS IgG negatively 
impacts evoked and nonevoked behaviors in mice.
Sensitization of nociceptors. Microneurography of FMS patients 
has demonstrated sensitization of nociceptive C-fibers (22). To 
determine whether the sensory abnormalities demonstrated in 
mice in vivo following administration of FMS patient IgG could be 
explained by a sensitization of peripheral nociceptors, we exam-
ined single afferent fiber units in skin–saphenous nerve prepara-
tions from IgG-treated mice. Single units were classified according 
to their conduction velocity and mechanical response threshold, 
as described previously (42, 43).
We stimulated the receptive fields of Aδ- and C-mech-
anosensitive nociceptors (AM and CM fibers) mechanically 
and compared the mechanical activation thresholds (the force 
required to elicit at least 2 action potentials during a 2-second 
challenge) after 4 days of treatment with HC or FMS IgG (Fig-
ure 6, A–C). Both AM and CM fibers in preparations from mice 
treated with FMS IgG responded to mechanical stimulation at a 
reduced force compared with preparations from HC IgG–treated 
mice (Figure 6, A–C). The reduced mechanical response thresh-
olds are consistent with the C-fiber sensitization observed in 
tions with IgG from individual patients (Figure 1), the pooled FMS 
IgG also elicited hypersensitivity to cold (Figure 3D). To determine 
the duration of the IgG-mediated hypersensitivity in more detail, 
we studied mechanical thresholds and cold latencies in mice treat-
ed with IgG pooled from patients or HC subjects for 1 month. The 
onset of hypersensitivities produced by pooled FMS IgG followed 
the same time course as seen with IgG from individual donors and 
resolved fully about 2.5 weeks after cessation of IgG administra-
Figure 3. Passive transfer of hypersensitivity by IgG pooled from multi-
ple patients. Visual analog pain scores (VAS, A) and pressure-pain thresh-
olds (PPT, B) in 2 pools of FMS patients and healthy control (HC) subjects. 
Pool 1, n = 8 FMS and n = 12 HC; Pool 2, n = 14 FMS and n = 10 HC. **P < 
0.01, ***P < 0.001 by Mann-Whitney U test. Administration of IgG pooled 
from FMS patients produced mechanical (C) and cold (D) hypersensitivity 
in mice compared with pooled HC IgG, 4 days after the first injection. Pool 
1, n = 6 mice per group; Pool 2, n = 12; line and whiskers indicate mean ± 
SEM. **P < 0.01, ***P < 0.001 by unpaired, 2-tailed t test. Time course 
of mechanical (E) and cold (F) hypersensitivity following administration 
of pooled IgG (Pool 1). *P < 0.05, FM vs. HC IgG; 2-way repeated measure 
ANOVA with Sidak’s correction. †P < 0.05, ††P < 0.01, compared with day 
zero; 2-way repeated measure ANOVA followed by Dunnett’s test. Data in 
E and F are mean ± SEM of 6 mice per group.
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pixel intensity were much greater in mice that had been injected 
with FMS IgG compared with IgG from HC subjects, and anti–
human IgG generated only minimal reactivity in DRG from saline- 
injected mice (Figure 7, B and C).
FMS patient IgG staining was primarily localized to satellite 
glial cells (SGCs, visualized by glutamine synthase staining) and to 
fiber tracts entering the DRG, as well as a small number of Iba1- 
positive macrophages and CD31-positive blood vessels (Figure 
7D). FMS IgG did not appear to colocalize with the neuronal nucle-
ar marker NeuN, which labels neuronal nuclei and to a lesser extent 
cytoplasm. Since NeuN does not label neuronal membranes and 
SGCs enwrap neurons with as little as 20 nm separation between 
the cells, it was challenging to distinguish neuronal membrane 
staining from that of the surrounding SGC (Figure 7D). We further 
explored the possibility that FMS IgG also labels the membranes 
of sensory neurons by using TrkA as a neuronal surface marker. In 
addition to the extensive FMS IgG labeling of glutamine synthase–
expressing SGCs (Figure 7, D and E), FMS IgG also appeared to 
label some, but not all, TrkA-expressing neurons (Figure 7E).
FMS IgG promotes expression of SGC activity markers. Since 
FMS IgG frequently colocalized with SGCs, we investigated 
whether this was associated with evidence of changes in SGC 
activity. We found that the positive area and pixel intensity of glial 
fibrillary acidic protein (GFAP) immunoreactivity (Figure 8, A and 
B) and Gfap and s100b gene expression (Figure 8C) in DRG from 
mice injected with FMS IgG were increased, compared with HC 
IgG–injected controls. These changes suggest that the presence of 
FMS IgG in DRG had increased the activity of SGCs. In contrast, 
the Iba1 percentage area of immunoreactivity in the neuron-rich 
area of the DRG was not different between FMS IgG– and HC 
IgG–injected mice (Figure 8, D and E), suggesting that FMS IgG 
accumulation in the DRG did not stimulate local macrophage 
proliferation or infiltration. However, Aif1 (encoding Iba1) and 
Itagm (encoding CD11b) were both elevated in the DRG of FMS 
IgG–injected mice (Figure 8F), indicating that certain aspects of 
macrophage activity were altered by FMS IgG. Importantly, there 
were few to no apoptotic cells in the DRG of mice injected with 
FMS or HC IgG (Supplemental Figure 3A), indicating that the 
effects of FMS IgG are not due to neuronal cell death. In contrast 
to the DRG, no changes in astrocyte and microglia reactivity were 
observed in the spinal cord based on GFAP (Supplemental Figure 
2, B–D) and Iba1 (Supplemental Figure 2, E–G) immunoreactivity, 
respectively. Together, these results suggest that FMS IgG has a 
local effect in the DRG.
FMS IgG does not induce cytokine production or systemic 
inflammation. Although there are inconsistencies between 
published studies, levels of inflammatory and immunomodu-
latory cytokines and chemokines, such as IL-6, IL-8, and IL-10, 
have been reported to be elevated in FMS serum or plasma (22, 
23) compared with HCs. Thus, we assessed a panel of factors 
in serum from mice injected with FMS IgG, HC IgG, or saline. 
IL-1β was below the limit of detection in 5 of 6 samples in each 
group, indicating that neither FMS IgG nor HC IgG induced 
IL-1β production. Similarly, there was no difference in TNF-α, 
CXCL1 (a murine analog of human IL-8), IL-2, IL-5, IL-6, IL-10, 
and IFN-γ levels between the groups (Figure 8, G–M). These 
data demonstrate that FMS IgG injection does not alter sys-
FMS patients using microneurography (22) and demonstrate 
that patient IgG produces a heightened peripheral nociceptor 
responsiveness that is maintained in the absence of the central 
nervous system. Since we had observed a robust behavioral cold 
hypersensitivity in mice treated with FMS IgG, we also exam-
ined whether this phenotype was accompanied by an increased 
cold responsiveness in mechanosensitive C-fibers (Figure 6, 
D–F). We challenged CM fibers with a 60-second cooling ramp 
(from 32°C to 5°C–9°C) and noted that a larger proportion of CM 
fibers responded to cold in preparations from mice treated with 
FMS IgG compared with HC IgG (Figure 6D). In contrast, FMS 
IgG did not influence the cold activation thresholds of cold- 
sensitive CM (Figure 6E). An increasing number of human dis-
orders are recognized as produced by functional autoantibodies 
that alter excitability by binding to neuronal surface proteins 
(44). We therefore challenged isolated neurons directly with 
a high concentration of FMS IgG (200 μg/mL), to determine 
whether FMS IgG directly excites dorsal root ganglia (DRG) 
neurons by such an interaction. We observed no effect of FMS 
IgG on intracellular Ca2+ concentration ([Ca2+]i) in any of the 870 
neurons examined (Figure 6G).
In vivo immunohistochemical localization of human IgG. Since 
CM and AM fibers were hypersensitive in mice treated with FMS 
IgG, we investigated the localization of FMS IgG to better under-
stand potential sites of action. In mice injected with pooled IgG, 
FMS IgG was consistently detected in DRG, but neither in brain 
nor spinal cord tissue by Western blot analysis (Figure 7A; see 
complete unedited blots in the supplemental material). Immuno-
histochemical analysis of tissues from mice that had been injected 
with pooled FMS IgG, using anti–human IgG antibodies to detect 
FMS IgG, revealed robust staining in the lumbar DRG (Figure 7, B 
and C), while no specific immunoreactivity was observed in the 
spinal cord (Figure 7A and Supplemental Figure 2A). The percent-
age area that was immunoreactive for human IgG as well as the 
Figure 4. IgG-depleted serum is inactive. IgG from an FMS patient, but 
not IgG-depleted serum from the same patient or pooled from FMS or HC 
cohorts, produced mechanical (A) and cold (B) hypersensitivities. **P < 
0.01, ***P < 0.01, FM vs. HC IgG; 2-way repeated measure ANOVA followed 
by Sidak’s correction. Data points are mean ± SEM of 6 mice per group.
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temic inflammatory and immunomodulatory cytokine levels. 
Together, the results suggest that FMS IgG acts by generating a 
local effect in the DRG.
In vitro immunohistochemical binding of FMS IgG. To further 
differentiate between labeling of SGCs and sensory neurons, we 
examined the immunoreactivity of FMS and HC IgG in SGC- 
enriched, sensory neuron–depleted cell cultures and dissociated 
DRG neuron–rich cell cultures. FMS IgG or HC IgG (pooled IgG, 
100 μg/mL) was added to the culture media prior to cell fixation 
in order to examine membrane labeling in a nonpermeabilizing 
condition. In SGC-enriched cultures, approximately 75% of cells 
were glutamine synthase–positive SGCs and less than 0.5% were 
neurons. FMS IgG bound to a significantly larger propor-
tion of cells (290 of 368 cells analyzed, 79%) compared 
with HC IgG (84 of 264 cells analyzed, 32%) (Figure 
9, A–C), and recognized these cells more strongly, as 
judged by pixel intensity (Figure 9D). Similarly, FMS IgG 
labeled a significantly larger proportion of both gluta-
mine synthase–positive (SGCs) and –negative cells (non-
SGCs) in these cultures and did so with a greater pixel 
intensity compared with HC IgG (Figure 9, E and F).
In dissociated DRG neuron cultures approximately 
30% of cells were βIII-tubulin–positive neurons (Figure 
9G). Similar to our observations with SGC-enriched cul-
tures, FMS IgG bound to a larger proportion of cells from 
dissociated DRG (358 of 527 cells analyzed, 68%) com-
pared with HC IgG (158 of 469 cells analyzed, 34%), and 
it also labeled these cells more intensely (Figure 9, H–J). 
Importantly, FMS IgG labeled almost all βIII-tubulin– 
positive neurons, whereas HC IgG labeled far fewer (Fig-
ure 9K). The pixel intensity of FMS IgG binding to neurons 
was greater than FMS IgG binding to non-neuronal cells, 
and greater than HC IgG binding to neurons and non-neu-
ronal cells (Figure 9L). Neither FMS IgG nor HC IgG 
affected cell viability compared with cells that were not 
incubated with antibodies (Supplemental Figure 3, B–E). 
Finally, incubating live cultures with IB4, a membrane 
marker of a subpopulation of nociceptors, demonstrated 
that FMS IgG binding colocalized with neuronal mem-
branes (Figure 9M). In conclusion, FMS IgG binds SGCs in 
vivo, and while further studies are warranted to determine 
if FMS IgG also binds to neuronal membranes in vivo, this 
possibility is supported by our data showing that FMS IgG 
binds both SGCs and neurons in vitro.
Reduced epidermal innervation. An involvement of 
peripheral sensory nerves in FMS has previously been 
indicated by observations of small-fiber pathology in 
patients (23, 45). Importantly, the symptom severity of 
FMS is correlated with the extent of small-fiber pathol-
ogy (33). We therefore examined the impact of IgG on 
intraepidermal nerve fiber density (IENFD) in the gla-
brous hind paw skin of mice. A significant reduction in 
IENFD was apparent 14 days after administration of FMS 
IgG was initiated, compared with skin sections from mice 
similarly treated with HC IgG (Figure 10, A and B).
Screening FMS IgG reactivity with human protein frag-
ments. To investigate whether FMS IgG from different 
patients contains a common pattern of autoreactivity, we used 
a proteome-wide microarray screen (SciLifeLab). This assay 
uses 42,000 human peptides (from >18,000 proteins) from the 
Human Protein Atlas (46, 47). The peptides in the array are linear, 
produced in E. coli, and most are between 50 and 150 amino acids 
in length. We examined the reactivity of 4 samples, each prepared 
from equal parts of 4 FMS patients’ sera (4×4), and noted that all 
4 samples recognized multiple peptides (signal > mean fluores-
cence intensity + [4 × SD]; Supplemental Table 5). However, our 
analysis also revealed that very few peptides were recognized by 
more than one of the pooled samples, strongly indicating that the 
antigens included in the array are unlikely to represent a common 
Figure 5. Passive transfer of FMS IgG decreases locomotor activity. Visual analog 
pain scores (VAS, A) and pressure-pain thresholds (PPT, B) reported by FMS patients 
and healthy control (HC) subjects in Pool 3. Following transfer of HC or FMS IgG to 
mice, locomotor activity was assessed over a 24-hour period using a Comprehensive 
Animal Lab Monitoring System. The total number of recorded movements was similar 
between HC IgG and FMS IgG mice during the day phase (low activity), but FMS 
IgG–injected mice showed less activity during the night phase (high activity) (C). The 
night phase was divided into 3 phases: 18:00–22:00 hours (D), 22:00–02:00 hours (E), 
and 02:00–06:00 hours (F), indicated by the dotted lines. Mice injected with FMS IgG 
displayed significantly less locomotor activity during the peak activity phase (E) com-
pared with HC IgG–injected mice. Data points are mean ± SEM, FMS n = 14, HC n = 11,  
n =12 mice per group. *P < 0.05, ***P < 0.001 by Mann-Whitney U test (A and B), 
2-way ANOVA followed by Bonferroni’s correction (C), or unpaired t test (D–F).
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autoantigen in FMS patients. Overrepresentation analysis (http://
webgestalt.org/; ref. 48) suggested some degree of enrichment 
for proteins associated with Gene Ontology (GO) terms related to 
cellular components and microtubules (Supplemental Table 6 and 
Supplemental Figure 4), and a small number of KEGG pathways 
related to metabolism and vesicle cycling (Supplemental Table 7 
and Supplemental Figure 5).
FMS IgG binds to human DRG. Finally, we assessed whether 
FMS IgG binds cells in human DRG. Human DRG sections were 
incubated with either pooled HC IgG or FMS IgG and the intensity 
and localization of binding were analyzed. FMS IgG bound cells 
in human DRG to a greater extent than HC IgG, as assessed by 
pixel intensity (Figure 11, A and B). Fur-
thermore, FMS IgG bound GFAP-im-
munoreactive cells and NF200- 
immunoreactive cells, indicating that FMS 
IgG binds to both human SGCs and human 
sensory neurons (Figure 11C). FMS IgG also 
labeled other cells, but less intensely. Taken 
together, these results suggest that FMS IgG 
contains autoreactive antibodies that bind 
antigens expressed in the DRG.
Discussion
Here we demonstrate that several key 
features of FMS can be induced in mice 
by IgG from individuals with FMS. Trans-
fer of hypersensitivities from patients to 
mice was reproducible across all tested 
FMS subjects, strongly suggesting that 
antibody-dependent processes typically 
underpin the characteristic tenderness 
and thermal hypersensitivities experi-
enced by patients. The pronociceptive 
effect of pooled IgG shows that samples 
from different patients have additive 
activity, since the IgG from each donor in 
these preparations was diluted to levels 
below those required to generate hyper-
sensitivity in mice. The behavioral hyper-
sensitivities produced by FMS IgG were 
reversible in mice and typically resolved 
after 2–3 weeks when the levels of human 
IgG have decreased (37). The reduction in 
grip strength and spontaneous locomotor 
activity, and the reduced density of epider-
mal innervation observed in mice treated 
with FMS IgG confirm that in addition to 
painful hypersensitivities, FMS IgG also 
produces several non-evoked symptoms 
and signs of FMS. IgG-depleted serum 
preparations were without any influence 
on mechanical or cold nociception, con-
firming that IgG is the principal pronoci-
ceptive, pathological serum component in 
FMS patients. Importantly, FMS IgG binds 
to SGCs and neurons in mouse and human 
DRG, strongly suggesting that FMS patients have autoreactive 
antibodies.
Interactions between the nervous and immune systems, 
and in particular autoimmune mechanisms, have increasingly 
attracted attention in studies of the pathophysiology of chronic 
pain conditions (49, 50). Pronociceptive effects of autoantibodies 
have been implicated in the uncommon posttraumatic condition 
complex regional pain syndrome (31, 51), where passive transfer 
of IgG additionally requires an experimental trauma to exert its 
pronociceptive effects, unlike the observations presented here for 
FMS IgG. In the very rare, frequently painful neurological condi-
tion neuromyotonia, autoantibodies against contactin-associated 
Figure 6. Passive transfer of FMS IgG sensitizes nociceptors. The mechanical activation thresholds 
of (A) Aδ- (AM) and (B) C-mechanonociceptors (CM) were reduced in preparations from mice treated 
with FMS compared with HC IgG (n = 22–27 single units). *P < 0.05 by 1-tailed Mann-Whitney U test. 
(C) The example trace illustrates a mechanical threshold response (evoked by the minimum force 
required to elicit at least 2 spikes) in a CM unit. (D) The proportion of cold-sensitive CM units (CMCs) 
was increased in preparations from mice treated with FMS IgG (21 of 29 units responded to cold) 
compared with HC IgG (13 of 28 units responded to cold). *P < 0.05 by 1-sided Fisher’s exact test. (E) 
The cold-activation thresholds of CMC fibers did not differ between FMS and HC preparations (n = 
13–21). P > 0.05 by 1-tailed t test. (F) The example trace illustrates a cold-evoked response in a CMC 
fiber. (G) Application of FMS IgG (200 μg/mL) to isolated DRG neurons loaded with Fura-2 was with-
out effect on [Ca2+]i in all 870 examined neurons (identified by their response to 50 mM KCl).  
The red trace illustrates the average time course of the displayed 230 neurons.
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to hypersensitivity (56–58). Additionally, the accumulation of 
SGC- and neuron-bound FMS IgG may stimulate molecular 
changes in DRG-resident macrophages that contribute to neuro-
nal hypersensitivity despite a lack of macrophage infiltration or 
proliferation. Furthermore, the absence of systemic increases in 
proinflammatory cytokines like TNF and IL-1β further supports 
our hypothesis that FMS IgG acts locally in the DRG, without 
inducing a systemic inflammatory response. Together, these 
findings point to the DRG as a site of action for FMS IgG and 
future studies will investigate the contributions of IgG acting on 
SGCs and neurons in driving pain-related sensory abnormalities 
and neuronal hypersensitivities in mice.
Although we did not discover a characteristic pattern of 
reactivities in patient sera in the protein microarray, we did note 
a substantial number of autoreactivities. Our results also indi-
cated some enrichment of reactivities against proteins classi-
fied in GO terms for cellular components, and KEGG terms for 
pathways related to metabolism. Although the potential enrich-
ment of reactivities may be encouraging, their relevance to the 
pathophysiology of FMS is currently unclear, since they were 
mostly detected in single samples. Furthermore, most proteins 
relevant to the potentially enriched terms are located intracellu-
larly and are thus unlikely to be recognized by circulating IgG. 
Genuine autoantigens may also have escaped detection, since 
the linearized antigenic protein fragments used in the screen are 
unlikely to adopt their native conformation on the chip (47). The 
peptides and protein fragments were produced in E. coli, and 
therefore lack posttranslational modifications. The prevalence 
of reactivities against human peptides in our preliminary assess-
ment of patient sera is nevertheless consistent with autoreactive 
IgG being responsible for our findings. Intriguingly, sera from 
COVID-19 patients contain a wide range of functional autoanti-
bodies, which have been proposed to influence the symptomatic 
profile in patients (59).
Small-nerve-fiber pathology and a reduction in skin innerva-
tion has been observed in FMS patients, and is associated with a 
more severe disease burden and may contribute to peripheral sen-
sitivity (33). Remarkably, we observed that transfer of FMS IgG to 
mice resulted in a reduction in IENFD in glabrous hind paw skin. 
In humans, it is still unclear why reduced skin innervation occurs, 
but our findings indicate that FMS IgG contributes to this fiber 
loss. FMS IgG may drive denervation from the DRG via SGC or 
neuronal cell body binding but may also act more distally through 
other mechanisms.
Future studies will examine the underlying cellular and molec-
ular mechanisms responsible for FMS IgG–mediated peripheral 
sensitization. The possibility that the heightened noxious periph-
eral input produced by FMS IgG may generate altered patterns 
of activity in the central nervous system (19) also remains to be 
explored. Similarly, whether FMS IgG drives sensitivity to other 
sensory modalities, such as to auditory and olfactory stimuli, still 
needs to be investigated. The identification of a pivotal role for 
autoreactive IgG in the pathophysiology of FMS may transform 
future research and facilitate development of mechanism-based 
therapeutic interventions. Our results suggest that therapies 
which reduce the total IgG titer, such as plasmapheresis or immu-
noadsorption (e.g., with protein A columns), or which specifically 
protein-like 2 (CASPR2) are commonly detected (28). Passive 
transfer of IgG from these patients produces painful hypersensi-
tivities by internalizing voltage-gated K+ channels. Our findings 
indicate that similarly nondestructive processes produce hyper-
sensitivities, motor symptoms, and loss of epidermal innervation 
in the common condition FMS.
The importance of altered central nervous system function 
and plasticity in FMS is illustrated by altered brain activity pat-
terns (19), glia activation in the brain (52), impaired conditioned 
pain modulation (53), and multisensory hypersensitivity to a wide 
range of stimuli (1, 54, 55). However, it is becoming increasingly 
clear that peripheral alterations also contribute to the underlying 
pathology, as exemplified by identification of small-fiber patholo-
gy in FMS patients (33) and altered cytokine levels (24). Here we 
found that mechanosensitive nociceptors in skin-nerve prepara-
tions from FMS IgG–treated mice displayed an increased respon-
siveness to mechanical and cold stimuli, strongly suggesting that 
painful hypersensitivity in FMS is produced by sensitization of 
peripheral nociceptors. In contrast, direct application of IgG to 
isolated DRG neurons was without effect on [Ca2+]i, consistent 
with an indirect action that may involve activity of an additional 
peripheral cell type, such as SGCs.
In combination with the electrophysiological observations, 
retention of FMS IgG in the DRG, the lack of IgG in the brain 
and spinal cord, and the in vivo binding of FMS IgG to SGCs and 
neurons strongly suggest that the pronociceptive actions of FMS 
IgG were driven by peripheral mechanisms. FMS IgG binding 
in human DRG and in vitro binding of FMS IgG to the surface 
of murine SGCs and neurons further emphasizes that the noci-
ceptive effects induced by FMS IgG may stem from recognition 
of epitopes in the DRG. Increased signs of in vivo SGC activity 
imply that FMS IgG binding in the DRG has functional effects. 
It is clear that SGCs and sensory neurons can be electrically cou-
pled and that both increased coupling and SGC-derived prono-
ciceptive cytokines can influence neuronal excitability leading 
Figure 7. FMS IgG accumulates in the DRG and binds satellite glial cells. 
Following IgG injection into mice, Western blot analysis detected FMS IgG 
in the DRG but little to no IgG in spinal cords (SC) or brains (A) (pooled IgG, 
8 mg per day for 4 consecutive days, tissue collected after last injection). 
FMS IgG, but not HC IgG, accumulates in the DRG 14 days after the first 
IgG injection (B and C). Human IgG is red and DAPI is blue. Human IgG 
immunoreactivity in the neuron-rich area was quantified by assessing the 
percentage area that was immunoreactive for human IgG and the mean 
pixel intensity of human IgG. Percentage area and pixel intensity were 
normalized to the DAPI signal (n = 9–10; data points are median ± 95% CI). 
**P < 0.01, ***P < 0.001 by 1-way ANOVA followed by Tukey’s post hoc 
test. FMS IgG immunoreactivity does not colocalize with neuronal NeuN 
staining but does colocalize with satellite glial cells (SGCs) (glutamate 
synthase–expressing [GS-expressing] cells), some macrophages (Iba1- 
expressing cells) and blood vessels (CD31-expressing cells), and myelinated 
fiber tracts (myelin basic protein [MBP] staining), but not to myelinated 
fibers in the DRG (D). To further delineate between SGCs and neuronal 
membranes, FMS IgG immunoreactivity colocalization was compared with 
GS and TrkA (a membrane receptor expressed by a subset of nociceptors). 
FMS IgG colocalizes with GS-expressing SGCs (white arrows) but may also 
infrequently bind to TrkA-positive neuronal cell membranes (white trian-
gles) (E). Scale bars indicate 50 μm, except the high-magnification image 
scale bar and scale bar in E, which indicate 25 μm.
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tigated whether primary sensory afferents were sensitized following 
transfer of FMS or HC IgG into mice using an ex vivo skin-nerve prepa-
ration. Third, we examined FMS IgG localization following transfer 
and cell-type binding in vivo and in vitro with Western blotting and 
immunofluorescence. Last, we assessed IgG-induced changes in skin 
innervation using immunofluorescence. Mechanical hypersensitivity 
is a hallmark of FMS and the Randall-Selitto paw-pressure test is a 
sensitive translational measure of this symptom.
Power calculations indicated that n = 4 would be sufficient to 
detect a 15-g reduction of the paw withdrawal threshold with α < 0.025 
and 1 – β > 0.9 (6 repeated measures, 2-sided), but n = 6 to detect a 
reduction in the cold-plate paw withdrawal latency of 2.5 seconds. 
Electrophysiological experiments were analyzed using 1-sided tests 
since we examined whether the increased sensitivity observed in vivo 
was associated with an increased (not decreased) single unit respon-
reduce autoreactive IgG (using antigen-specific adsorption) may 
be effective for FMS (60). Alternatively, symptomatic therapies 
that interfere with the binding of autoreactive antibodies or pre-
vent their functional consequences may also provide effective 
treatment approaches.
Methods
Study design. Our goal was to determine whether administration of IgG 
from FMS patients to mice transfers characteristic symptoms of FMS. 
FMS patients and age-matched HC individuals were recruited at 2 dif-
ferent sites, the University of Liverpool and the Karolinska Institute, 
where serum was collected and IgG was purified. First, we assessed 
whether IgG from FMS patients drove pain-like behavior in mice by 
transferring IgG from single individuals into mice as well as transfer-
ring IgG pooled from several individuals into mice. Second, we inves-
Figure 8. FMS IgG increases signs of satellite glial cell activity in vivo but does not drive systemic inflammation. DRG from FMS IgG–injected mice have 
increased GFAP immunoreactivity (A), which is indicative of increased satellite glial cell activity, compared with HC IgG injected mice when the percentage 
area of GFAP immunoreactivity and GFAP mean pixel intensity are quantified and normalized to the DAPI signal (B). Gfap and s100b gene expression is 
elevated in the DRG of mice injected with FMS IgG compared with HC IgG (C). The number of Iba1-immunoreactive macrophages was unchanged, as was 
the percentage area of Iba1 immunoreactivity, when comparing HC IgG– and FMS IgG–injected mice (D and E). Gene expression of Aif1 (Iba1 gene) and 
Itagm (gene for CD11b, another macrophage marker) was elevated in FMS IgG–injected mice compared with HC IgG–injected mice (F). Scale bars: 50 μm. 
qPCR data were normalized to Hprt1 expression analyzed using the 2–ΔΔCt method. Serum levels of TNF (G), CXCL1 (H), IL-2 (I), IL-5 (J), IL-6 (K), IL-10 (L), and 
IFN-γ (M) were measured and there were no differences between groups. The dashed lines indicate the lower limit of quantification (LLOQ) and the dotted 
lines indicate the lower limit of detection (G–M). Line and whiskers indicate mean ± SEM (n = 4–6). Differences between FMS IgG and HC IgG were analyzed 
with Mann-Whitney U test (B–F). Cytokine levels were compared between saline, HC, and FMS with 1-way ANOVA followed by Tukey’s post hoc test for 
each analyte (G–M) except IL-6, which was not analyzed statistically because most values were below the LLOQ. *P < 0.05, **P < 0.01, ***P < 0.001.
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tute. Immunofluorescence, Western blotting, and qPCR experiments 
were performed with tissues from behavioral experiments using IgG 
pools. Immunocytochemistry experiments were performed using IgG 
pools. Sample sizes for each experiment are additionally indicated in 
the figure legends.
siveness. All other data were analyzed using 2-sided tests. Behavioral 
(except the Comprehensive Animal Lab Monitoring System [CLAMS]) 
and electrophysiological experiments were performed at King’s Col-
lege London and CLAMS, immunofluorescence, Western blotting, 
qPCR, and cell culture studies were performed at the Karolinska Insti-
Figure 9. FMS IgG binds to satellite glial cells and to neurons in vitro. Live cells were incubated with FMS IgG or HC IgG to examine only cell surface 
binding. In satellite glial cell (SGC) cultures (A), FMS IgG labeled a greater percentage of cells than HC IgG when analyzed per animal (B) and by the total 
number cells (C). The immunoreactivity, analyzed as signal intensity (integrated density), was higher in cells incubated with FMS IgG than HC IgG (D). 
FMS IgG labeled SGCs (GS+) and non-SGCs (GS–) to a greater extent (percentage, E) and with a higher intensity (F) than HC IgG. FMS and HC IgG labeling 
of neuronal cultures (G) was not different when considering the percentage of cells labeled per animal (H), but a difference was observed when the total 
number of cells was considered (I). The signal intensity was higher for cells exposed to FMS IgG than HC IgG (J). FMS IgG labeled neurons (βIII-tubulin+) and 
non-neurons (βIII-tubulin–) to a greater extent than HC IgG (K). The signal intensity of FMS IgG binding to neurons was greater than FMS IgG binding to 
non-neuronal cells and HC IgG binding to all cells (L). FMS IgG and IB4 colocalization (M) indicates that FMS IgG binds neuronal cell membranes. All scale 
bars: 20 μm. Data points are the percentage of cells bound by HC or FMS IgG (B and H). In D, F, J, and L data points are the integrated density of individual 
cells across 3 experiments. Bar and whiskers indicate mean ± SEM (n = 3 individual experiments). *P < 0.05; ***P < 0.001 by unpaired t test (B, D, H, and J), 
χ2 test (C, E, I, and K), or Kruskal-Wallis test with Dunn’s post hoc test (F and L).
The Journal of Clinical Investigation R E S E A R C H  A R T I C L E
J Clin Invest. 2021;131(13):e144201  https://doi.org/10.1172/JCI1442011 2
10K); concentration measurements were performed 
using a Nanodrop 2000 (Thermo Fisher Scientific). 
Before eluting the IgG from the protein G column, 
the IgG-depleted sera (flow through) was collected 
and stored at –80°C for later use. Prior to injection, 
the flow through was concentration-adapted using 
PBS-prewet concentration columns and the concen-
tration was determined with a Nanodrop 2000.
Animals. Behavioral experiments were per-
formed on female C57BL/6J mice (8–10 weeks old) 
obtained from Envigo UK Ltd and housed in a tem-
perature-controlled environment with a 12-hour 
light/12-hour dark cycle with access to food and 
water ad libitum. Locomotor activity assessment and 
immunofluorescence experiments were performed 
on 4-month-old female BALB/c mice (Janvier). Mice 
were injected intraperitoneally with IgG from HC 
subjects or FMS patients on 1–4 consecutive days.
Behavioral studies. Before any nociceptive test-
ing, mice were kept in their holding cages to acclima-
tize (10–15 minutes) to the experimental room. Mice 
were randomized between cages and the experi-
menter was blinded to their treatment.
The Randall-Selitto paw-pressure test was performed using an 
Analgesy-Meter (Ugo-Basile). The experimenter lightly restrained 
the mouse and applied a constantly increasing pressure stimulus to 
the dorsal surface of the hind paw using a blunt conical probe. The 
nociceptive threshold was defined as the force in grams at which the 
mouse withdrew its paw (64). A force cutoff value of 150 g was used to 
avoid tissue injury. The thigh-pressure test was also performed using an 
Analgesy-Meter. A constantly increasing pressure was applied to the 
inner thigh muscle of lightly restrained mice, using a blunt, wedge-
shaped probe and the force at which the mouse withdrew its leg was 
recorded as the nociceptive threshold.
Tactile sensitivity was assessed using von Frey filaments (0.008–2 
g) according to Chaplan’s up-down method (65). Animals were placed 
in a Perspex chamber with a metal grid floor allowing access to their 
plantar surface and allowed to acclimatize prior to the start of the 
experiment. The von Frey filaments were applied to the plantar surface 
of the hind paw with enough force to allow the filament to bend, and 
held static for approximately 2–3 seconds. The stimulus was repeated 
up to 5 times at intervals of several seconds, allowing for resolution 
of any behavioral responses to previous stimuli. A positive response 
was noted if the paw was sharply withdrawn in response to filament 
application or if the mouse flinched upon removal of the filament. 
Any movement of the mouse, such as walking or grooming, was 
deemed an unclear response, and in such cases the stimulus was 
repeated. If no response was noted, a higher-force hair was tested and 
the filament producing a positive response recorded as the threshold.
Thermal sensitivity was assessed using a cold plate (Ugo Basile). 
Paw withdrawal latencies were determined with the plate set at 10°C. 
The animals were lightly restrained (scruffed) and the left hind paw 
was placed onto the surface of the plate (66, 67). The latency to with-
drawal of the paw was recorded as the endpoint. A maximum cutoff of 
30 seconds was used for each paw.
Forelimb grip strength performance was assessed using a commer-
cially available grip strength meter (Ugo Basile), incorporating a T-bar 
Patient samples. Serum samples for individual testing were 
derived from UK patients managed for their fibromyalgia at a depart-
ment of pain medicine, or from age- and sex-matched HCs between 
April 2017 and November 2018. Pooled samples were obtained from 
Swedish patients between September 2015 and December 2016 or 
HCs responding to a study advert between March 2016 and March 
2017. All patients had been examined by a consultant rheumatolo-
gist, and UK patients had additionally been examined by a consul-
tant in pain medicine.
We purified serum IgG from 44 FMS patients and 39 HC sub-
jects. All patients fulfilled both 1990 and 2011 ACR diagnostic cri-
teria for fibromyalgia (61, 62). Most patients (42 of 44) and all of the 
pooled-sample donors were unaffected by other sensory, autoim-
mune, or rheumatological conditions. Most patient donors (43 of 44) 
were women. The donors’ demographics and disease characteristics 
are provided in Supplemental Tables 1 and 2.
Purification of immunoglobulins. IgG for individual testing was 
purified as described previously (63), using protein G beads (Sigma- 
Aldrich). Serum was diluted 1:3 with Hartmann’s solution, passed 
through a protein G column, and the bound IgG was eluted using 100 
mM glycine pH 2.3; after elution the pH was adjusted to 7.4 using 1 M 
Tris pH 8 and then the eluate was dialyzed overnight at 4°C in Hart-
mann’s using a 10 kDa dialysis membrane (Thermo Fisher Scientific). 
The concentration of IgG present after dialysis was determined using 
a modified Lowry assay (DC protein assay, Bio-Rad) and adjusted by 
dilution with Hartmann’s or by concentrating dialysis against a sucrose 
solution (Sigma-Aldrich). Finally, the IgG solution was sterile filtered 
using syringe-driven 0.2 μm filter units (Millipore), stored at 4°C, and 
used within 3 months. Sera for pooled sample testing were purified 
using HiTrap Protein G HP columns (GE Healthcare), eluted with 0.1 M 
glycine/HCl pH 2.7, and the pH adjusted to 7.4 with 1 M Tris pH 9; con-
sequently, samples were dialyzed against PBS, concentration adjusted, 
stored at –20°C, and later thawed, pooled, and concentration-adapted 
using PBS-prewet concentration columns (Pall Corporation, Macrosep 
Figure 10. FMS IgG transfer decreases intraepidermal nerve fiber density. Intraepidermal 
nerve fibers (IENFs) were identified in the glabrous hind-paw skin with an anti–PGP 9.5 
antibody (A). The number of IENFs crossing from the dermis to the epidermis was decreased 
following transfer of FMS IgG compared with HC IgG 14 days after the first injection (B) (pooled, 
8 mg per day for 4 consecutive days). Scale bar: 20 μm. Data points are mean ± SEM (n = 7). *P 
< 0.05 by unpaired t test.
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26.2 mM NaCO3, 1.65 mM NaH2PO4, 1.53 mM CaCl2, 9.6 mM sodium 
gluconate, 5.55 mM glucose, and 7.6 mM sucrose. The skin was 
placed inside up (corium side up) and pinned down using insect pins 
(0.2 mm diameter) in the organ bath to allow access to the receptive 
fields. The saphenous nerve was threaded through a small gap from 
the organ bath to an adjacent recording chamber and positioned on a 
mirror platform. The desheathed saphenous nerve was covered with 
paraffin oil for electrical isolation and the dissected fine nerve fila-
ments were visualized with a microscope and placed on a gold wire 
recording electrode (42, 43).
Conduction velocity. The saphenous nerve was divided into pro-
gressively thinner filaments until a single unit could be isolated in 
response to mechanical stimulation of the receptive field with a 
glass rod. The electrical latency of identified units (Digitimer DS2, 
Digitimer Ltd) was used to determine the conduction velocity and to 
categorize units as Aβ (velocity > 10 m/s), Aδ (1.2 < velocity < 10 m/s), 
or C-fibers (0 < velocity < 1.2 m/s).
Mechanical and cold stimulation. A computer-controlled stim-
ulating probe, equipped with a force transducer, was used to deliver 
mechanical stimuli to the most sensitive point of a receptive field 
(Avere Solutions UG) of AM and CM fibers in preparations from mice 
treated with FMS or HC IgG. Recording and analysis were done using 
Spike 2 (Cambridge Electronic Design). Cold sensitivity of CM units 
and force transducer. The mice were held gently by the base of the tail 
and pulled across the horizontal T-bar so that they were able to grip the 
bar with their fore paws. A digital readout of the maximum force applied 
is given once the grip is released. Mice were acclimatized to the appara-
tus by testing twice prior to starting the study. The test was performed at 
least twice on each mouse and the mean force value used.
Locomotor activity was assessed with CLAMS (Columbus Instru-
ments) cages for 48 hours. Mice were singly housed and habituated to 
the cages for 24 hours starting during the night 4 days following anti-
body injection. Following habituation, locomotor activity was assessed 
by beam-break recording. The CLAMS cage has a grid of infrared beams 
in the x-y plane and records infrared beam breaks that result from the 
mouse moving in the cage. Beam breaks are counted and used to assess 
the total movement of the mouse over a 24-hour period. Total move-
ment is analyzed by the number of beam breaks (counts) in 20-minute 
bins over a 24-hour period. The night phase (peak activity phase) was 
further subdivided in to 4-hour bins from 18:00–6:00 hours.
Skin-nerve recording. Mice were killed by cervical dislocation and 
the hind paw was shaved prior to dissection of the isolated skin-nerve 
preparation. The saphenous nerve and the shaved skin of the hind 
limb were placed in a recording chamber at 32°C. The chamber was 
perfused with a gassed (95% O2 and 5% CO2), prewarmed, synthetic 
interstitial fluid (SIF): 108 mM NaCl, 3.5 mM KCl, 0.7 mM MgSO4, 
Figure 11. FMS IgG binds human DRG. FMS IgG bound human 
DRG tissue sections more intensely than HC IgG when assessed 
by integrated density normalized to DAPI (A and B). The indicated 
IgG is in white in the top row and DAPI is in blue in the bottom row 
of A. High-magnification images of FMS IgG (white) demonstrate 
colocalization (purple) with GFAP-immunoreactive satellite glial cells 
(green) and NF-200–immunoreactive neurons (green) (C). Scale bars: 
50 μm (A) and 20 μm (C). Data are mean ± SEM (n = 5 independently 
stained slides). ***P < 0.001 by unpaired t test.
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sity. Macrophage number was calculated by counting the number 
of Iba1-immunoreactive cells in the neuron-rich area of the DRG. 
IENFD was determined by counting the number of fibers crossing 
from the dermis to the epidermis. Spinal cords were imaged using a 
Nikon Eclipse TE300 fluorescence microscope with a Nikon Digital 
Sight DS-Fi1 camera. Spinal Iba1 and GFAP signal intensity was ana-
lyzed by 2 blinded reviewers using a custom-developed Python script. 
Data were then normalized to the DAPI pixel intensity. For DRG and 
spinal cords, 4–5 sections from each animal, separated by at least 50 
μm, were analyzed and averaged for each experiment. For skin, 4 sec-
tions from each animal separated by at least 80 μm were analyzed and 
averaged. Data are presented as mean ± SEM. Representative spinal 
cord images were taken using a Zeiss LSM 800 confocal microscope.
Cell culture. DRG and SGC-enriched/neuron-depleted cultures 
were established using a modified protocol based on Malin et al. (68). 
Briefly, approximately 40 DRG were collected from each mouse and 
enzymatically digested in Papain (Worthington Biochemical Corp.) 
for 30 minutes and then in a Collagenase II (Worthington Biochem-
ical Corp.)/Dispase (Sigma-Aldrich) mixture for 30 minutes. Fol-
lowing digestion, cells were suspended in F-12 media (Gibco) with 
10% fetal bovine serum (FBS, Gibco) and 1× penicillin-streptomycin 
(Gibco). Gentle trituration was used to form a single-cell suspension. 
DRG cultures that were used for neuron staining were seeded into 
Nunc Lab-Tek II CC2-treated chamber slides (Thermo Fisher Scien-
tific). SGC-enriched/neuron-depleted cultures were established by 
seeding cells into uncoated glass Nunc Lab-Tek chamber slides and 
1.5 hours after seeding the media and nonadherent cells, including 
neurons, were removed; adherent cells were washed one time with 
fresh media, and fresh media were then added to the adherent cells. 
Cultures were kept in an incubator at 37°C with 5% CO2. Cultures were 
allowed to recover for approximately 20 hours prior to immunocyto-
chemistry or TUNEL staining.
Reagents. All buffers and salts were purchased from Sigma- 
Aldrich, VWR, or Thermo Fisher Scientific.
Statistics. Data are presented as individual data points or as mean 
± SEM, unless stated otherwise, and the number of animals or sin-
gle units studied are indicated by n. Outliers in the immunofluores-
cence integrated density analysis were removed using the ROUT test; 
otherwise, no data points have been removed from any of the data sets 
presented. Data from behavioral in vivo experiments, most in vivo 
and in vitro immunofluorescence data, and qPCR data were assessed 
statistically by unpaired, 2-tailed t test, Mann-Whitney test, 2-way 
repeated measure ANOVA followed by Sidak’s or Dunnett’s post hoc 
test, or 1-way ANOVA followed by Tukey’s post hoc test. Patient data 
and electrophysiological data were evaluated by Mann-Whitney U 
test. Differences in the distribution of cells bound by FMS or HC IgG 
were assessed by the χ2 test. Comparisons with a P value of less than 
0.05 were considered statistically different.
Study approval. Serum collection received ethical approval (UK: 
Ethics North-West Haydock, ref. 15/NW/0467; Sweden: approved by 
the local ethical committee 2011/2036–31/1) and samples were col-
lected from individuals following written informed consent. A human 
DRG was collected from an organ donor following consent from the 
next of kin and received approval by the institutional review board 
(McGill University Health Centre REB 2019-4896). Behavioral exper-
iments were carried out according to the UK Home Office Animal 
Procedures (1986) Act. All procedures in the UK were approved by the 
was investigated by isolating the receptive field with a metal ring and 
a 60-second cold ramp (~31°C–4°C) was applied by superfusing pre-
cooled SIF. Peristaltic pumps were used to control the SIF flow rate. A 
digital temperature probe (GIA 2000, Greisinger) was placed inside 
the ring to record the temperature at the skin. A response was consid-
ered positive if a minimum of 2 action potentials were evoked and the 
temperature at which the second action potential fired was recorded 
as the cold threshold.
Immunofluorescence. Mice were deeply anesthetized with iso-
flurane and perfused with PBS, followed by 4% paraformaldehyde 
(PFA). The lumbar spinal cord, lumbar DRG, and hind paw glabrous 
skin were collected, postfixed for 24 hours in 4% PFA, cryoprotected 
in 20% sucrose, and then embedded in optimal cutting tempera-
ture (OCT) compound (Sakura Finetek). Tissue was sectioned with a 
CryoStar NX70 cryostat (Thermo Fisher Scientific) at a thickness of 
10 μm and thaw mounted onto SuperFrost Plus slides (Thermo Fisher 
Scientific) and slides were stored at –20°C until use. Prior to use, 
slides were thawed for at least 30 minutes at room temperature and 
washed in PBS to remove excess OCT. Slides were blocked with PBS 
supplemented with 0.3% Triton X-100 and 3% normal goat or don-
key serum, depending on the secondary antibody, and then incubated 
with primary antibodies diluted in PBS supplemented with 0.1% Tri-
ton X-100 and 1% normal goat or donkey serum. Slides were washed 
and incubated with appropriate secondary antibodies (indicated in 
Supplemental Table 4). For colocalization studies of human IgG with 
various cell-type markers the primary antibodies against the cell-type 
markers were first added, and then following washing, the anti–human 
IgG antibody was coincubated with the secondary antibodies against 
the cell-type marker primary antibodies. Following washing, the slides 
were incubated with DAPI (1:20,000), washed again, and then covers-
lipped with Prolong Gold mounting media (Thermo Fisher Scientific).
A human DRG was collected from a 53-year-old female without 
a history of chronic pain who died following a head trauma. The DRG 
was flash frozen at the time of collection and stored at –80°C until it 
was embedded in OCT. Tissue was sectioned at a thickness of 14 μm 
and mounted onto SuperFrost Plus slides and stored at –80°C until 
use. For staining, sections were fixed for 30 minutes with cold 4% 
PFA, washed with PBS, blocked with PBS supplemented with 0.3% 
Triton X-100 and 3% normal goat serum for 1 hour, and incubated 
overnight with 100 μg/mL unconjugated anti–human IgG Fab frag-
ments (H+L, Jackson Immunoresearch). Following washing, slides 
were incubated overnight with pooled FM or HC IgG (15 μg/mL) 
diluted in PBS with 1% normal goat serum and 0.1% Triton X-100. 
Slides were then washed and incubated with appropriate second-
ary antibodies for 2 hours. Antibodies against NF200 or GFAP were 
applied for 2 hours, and then slides were washed and incubated with 
appropriate secondary antibodies. Following washing, the slides were 
incubated with DAPI (1:10,000), washed again, and then coverslipped 
with Prolong Gold mounting media.
Fluorescence microscopy and analysis. DRG were imaged using 
a confocal microscope (Zeiss LSM800) operated by LSM ZEN2012 
(Zeiss) software. Human IgG accumulation and GFAP and Iba1 sig-
nal intensity were analyzed in ImageJ (NIH) by defining a region of 
interest around the neuron-rich area of the DRG, applying a minimum 
pixel intensity threshold, and then the percentage positive area above 
the threshold and the average pixel intensity above the threshold 
were evaluated. Data were then normalized to the DAPI pixel inten-
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critical reading of the manuscript and gave their consent for the 
final draft. The order of the co–first authors, AG and E Krock, was 
determined alphabetically.
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